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risk factors that confer a 10-year calculated 
cardiac risk greater than 20%.1 
Statin dosage: Bigger is better
Th e Treating to New Targets (TNT) study 
showed that in patients with stable CHD, 
intensive lipid lowering with atorvastatin 
80 mg daily delivered signifi cant clinical 
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Evidence summary
Th e National Cholesterol Education Pro-
gram’s defi nition of “very high risk” for cor-
onary heart disease (CHD) encompasses 
established CHD and CHD equivalents, in-
cluding diabetes, peripheral arterial disease, 
abdominal aortic aneurysm, symptomatic 
carotid artery disease, and multiple cardiac 
EVIDENCE-BASED ANSWER
A not much. No studies directly  compare low-density lipoprotein 
(LDL) levels <70 mg/dL to levels of 71 to 
100 mg/dL in very-high-risk patients. How-
ever, no evidence suggests a “fl oor” for 
LDL cholesterol levels beyond which fur-
ther reductions of heart disease risk can’t 
be achieved (strength of recommendation 
[SOR]: A, systematic reviews of randomized 
controlled trials [RCTs]). Th e target LDL 
cholesterol of <70 mg/dL is based on data 
extrapolated from RCTs (SOR: B). 
Comparing larger (80 mg) with small-
er doses of atorvastatin shows that larger 
doses reduce LDL and major cardiac events 
more than smaller doses. No studies report 
patient-oriented outcomes of treatments for 
patients who fail to reach target LDL levels 
<100 mg/dL.
CLINICAL COMMENTARY
Treatment benefi ts—and potential barriers
As this review demonstrates, patients at very 
high risk of coronary artery disease may de-
rive benefi t from lowering LDL cholesterol to 
<70 mg/dL. Attempting to reach this goal for 
such patients seems to be a “no-brainer.” In 
reality, however, several possible barriers to 
treatment exist, including: 
 •   Th e goal may be unachievable, even 
with the highest dose of statins, combi-
nation therapy, and lifestyle changes. 
 •   Th e risk of myopathy (which is rare) or 
adverse side eff ects (less rare) is propor-
tional to the statin dose and may prevent 
certain patients from achieving the goal.
 •   For most statins, cost increases with 
dosage.
 •   For patients with multiple comorbidities, 
the incremental health benefi t of intensive 
LDL lowering may not be signifi cant. 
As with any medical intervention, you 
should explain all risks and benefi ts to the 
patient, who should participate actively in 
the decision to pursue the goal of intensively 
lowering LDL cholesterol. 
Wail Malaty, MD 
Mountain Area Health Education Center Family Practice 
Rural Residency, University of North Carolina School of 
Medicine, Hendersonville
Carrie Nelson, MD, MS
Rush-Copley Family Medicine 
Residency Program, 
Rush Medical College, 
Aurora, Ill
Kristin Hitchcock, MSI 
American Academy 
of Orthopaedic Surgeons,
Rosemont, Ill
James A. Bohlen, MLS
Rush-Copley Medical Center, 
Aurora, Ill 
666 THE JOURNAL OF FAMILY PRACTICE  |   DECEMBER 2009  |   VOL 58, NO 12
benefi t beyond that provided by atorvastatin 
10 mg daily.2 Th e mean LDL achieved in TNT 
was 77 mg/dL on 80 mg atorvastatin, com-
pared with 101 mg/dL on 10 mg.
Patients with diabetes who took 80 mg 
had a 2.26% absolute risk reduction for ma-
jor cardiovascular events (number needed 
to treat=43). Secondary outcomes—includ-
ing all cardiovascular events, cerebrovascu-
lar events, and congestive heart failure with 
hospitalization—also improved on 80 mg 
atorvastatin. 
Although this study enrolled a total of 
10,001 patients with clinically evident CHD, it 
was not suffi  ciently powered to demonstrate 
diff erences in overall mortality between the 
2 groups. While it is clear that patients in the 
80-mg group had better outcomes than pa-
tients in the lower-dose group, the exact role 
of LDL lowering cannot be easily separated 
from other potentially benefi cial eff ects of the 
higher dose of atorvastatin.
How low should LDL go?
What the studies show
In the Heart Protection Study, patients with 
CHD, other occlusive arterial disease, or dia-
betes were randomized to 40 mg simvastatin 
or placebo.3 Simvastatin reduced relative risk 
of CHD—regardless of baseline LDL—even in 
patients with a baseline LDL <116 mg/dL. 
Further analysis showed that among 
the many types of high-risk patients, 5 years 
of simvastatin at 40 mg daily would prevent 
about 70 to 100 people in 1000 from suff ering 
at least 1 major vascular event (myocardial 
infarction, stroke, or the need for revascular-
ization). Interestingly, patients with relatively 
smaller reductions in LDL (those in the low-
est third) showed the same decrease in CHD 
events as patients in the highest third—al-
though the overall diff erence in LDL wasn’t 
large. 
A meta-analysis of these and other stud-
ies concluded that intensive lipid lowering 
with high-dose statin therapy confers a sig-
nifi cant benefi t over standard-dose therapy 
for preventing predominantly nonfatal car-
diovascular events.4 Th e safety and tolerabil-
ity of higher and standard statin doses are 
similar.2 Two additional meta-analyses sup-
ported the use of intensive statin regimens 
to reduce cardiovascular risk, but didn’t fi nd 
evidence for lowering LDL to a particular tar-
get level.5,6 
Meta-analysis: The lower the LDL, 
the lower the risk of CHD
Th e ENHANCE study, a double-blind, ran-
domized trial conducted over a period of 
24 months, compared the eff ects of 80 mg 
per day of simvastatin with either placebo or 
10 mg per day of ezetimibe in 720 patients 
with familial hypercholesterolemia. Th e pri-
mary outcome measure was a change in inti-
ma-media thickness of the walls of the carotid 
and femoral arteries. Th e results of the study 
have raised the question of whether it is ap-
propriate to target LDL cholesterol primarily 
to reduce CHD risk, because ezetimibe did 
not aff ect carotid artery intima-media thick-
ness, despite its eff ectiveness in reducing 
LDL cholesterol.7
However, an earlier 19-trial meta-
regression analysis (81,859 patients with sta-
ble CHD) demonstrated that each 1% reduc-
tion in LDL cholesterol corresponded to a 1% 
decrease in risk for CHD. Th is result held true 
regardless of diff erent approaches to treat-
ment, which included diet, bile-acid seques-
trant, statins, or ileal bypass surgery.8 
Recommendations
Th e Adult Treatment Panel (ATP) III guide-
lines recommend an LDL level <100 mg/dL 
for high-risk patients (CHD or a CHD risk 
equivalent).9 An update to the ATP III guide-
lines states that the LDL goal of <100 mg/dL 
was as low as could be supported by clinical 
trial evidence at the time of publication and 
was also the practical limit of LDL reduction 
that could be achieved with standard treat-
ment in most high-risk patients.1 Th e ATP 
III update off ers the option of treating high-
risk patients to a target LDL <70 mg/dL and 
clarifi es that recent trials have shown no sig-
nifi cant side eff ects associated with very low 
LDL levels.
Recent American Diabetes Association 
guidelines state that the LDL target should be 
<100 mg/dL in patients with diabetes, with the 
option of treating patients with both overt CHD 
and diabetes to an LDL of <70 mg/dL.10 
No evidence 
points to a 
“ﬂ oor” for LDL 
cholesterol 
levels beyond 
which further 
reductions of 
heart disease 
risk can’t be 
achieved.
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